08:51 AM EDT, 05/02/2024 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) , a biotechnology company working on optimizing drug delivery, formed a clinical advisory board for its gastrointestinal program.

The Board, comprised of gastrointestinal experts, will work with Eupraxia as it develops its lead candidate EP-104GI for eosinophilic esophagitis, which is currently in a Phase 1b/2a clinical trial.

"The formation of our Gastrointestinal Clinical Advisory Board comes at an exciting time for our company, as we continue to generate clinical evidence in support of EP-104GI for the treatment of eosinophilic esophagitis," said Mark Kowalski, chief medical officer of Eupraxia. "As we advance the EoE program, we will now have access to an extraordinary group of renowned GI experts who will provide key insights and recommendations to help guide the program toward advanced stages of clinical development."

EoE is an inflammatory disease in which white blood cells migrate into and become trapped in the esophagus, creating pain and difficulty when swallowing food.